Novel drug developmental strategies for treatment‐resistant depression

• Published in: British journal of pharmacology Vol. 179; no. 6; pp. 1146 - 1186
• Main Authors: Borbély, Éva, Simon, Mária, Fuchs, Eberhard, Wiborg, Ove, Czéh, Boldizsár, Helyes, Zsuzsanna
• Format: Journal Article
• Language: English
• Published: England Blackwell Publishing Ltd 01.03.2022; John Wiley and Sons Inc
• Subjects: Animal models; Animals; antidepressant; Antidepressive Agents - pharmacology; Antidepressive Agents - therapeutic use; Antipsychotics; Clinical trials; Depression - drug therapy; Depressive Disorder, Major - drug therapy; Depressive Disorder, Treatment-Resistant - drug therapy; Drug Development; glutamate; Glutamatergic transmission; Glutamic acid receptors (ionotropic); Glutamic acid receptors (metabotropic); Humans; Inflammation; Ketamine; Mental depression; Molecular modelling; monoamine; N-Methyl-D-aspartic acid receptors; Neuroimaging; neuroinflammation; neuroplasticity; Neuroprotection; Neuroprotective agents; Neurotransmission; opioid; Review; Therapeutic targets; Treatment resistance; Tryptamine; neuroinflammation; monoamine; antidepressant; opioid; glutamate; neuroimaging; neuroplasticity

Major depressive disorder is a leading cause of disability worldwide. Because conventional therapies are ineffective in many patients, novel strategies are needed to overcome treatment‐resistant depression (TRD). Limiting factors of successful drug development in the last decades were the lack of (1...